McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a June 30, 2015 online edition of Managing Intellectual Property in an article entitled, “”Biotech Companies Consider Trade Secrets as Alternative to Patents.” Speakers at the 2015 BIO International Convention in Philadelphia this month expressed concern about the effect of US court decisions related to Section 101 of the Patent Act. The Supreme Court has narrowed what is eligible under 101 in recent years through decisions such as Alice, Myriad and Mayo. View the article